Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol
Brief Summary: Trial to evaluate efficacy of dual blockade with two anti-HER2 agents with or without chemotherapy backbone within the ADAPT trial.


Options:
A: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Trastuzumab, Drug: Pertuzumab | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trastuzumab, Drug: Pertuzumab, Drug: Paclitaxel | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Pertuzumab; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm B
B: Arm Label: Standard Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Therapy | Arm Label: AMG 386 with or without Trastuzumab; Type: EXPERIMENTAL; Interventions: Drug: AMG 386 with or without Trastuzumab, Drug: AMG 386 and Trastuzumab | Arm Label: AMG 479 plus Metformin; Type: OTHER; Interventions: Drug: AMG 479 (Ganitumab) plus Metformin | Arm Label: MK-2206 with or without Trastuzumab; Type: EXPERIMENTAL; Interventions: Drug: MK-2206 with or without Trastuzumab | Arm Label: T-DM1 and Pertuzumab; Type: EXPERIMENTAL; Interventions: Drug: T-DM1 and Pertuzumab | Arm Label: Pertuzumab and Trastuzumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pertuzumab and Trastuzumab | Arm Label: Ganetespib; Type: EXPERIMENTAL; Interventions: Drug: Ganetespib | Arm Label: ABT-888; Type: OTHER; Interventions: Drug: ABT-888 | Arm Label: Neratinib; Type: OTHER; Interventions: Drug: Neratinib | Arm Label: PLX3397; Type: EXPERIMENTAL; Interventions: Drug: PLX3397 | Arm Label: Pembrolizumab 4 cycle; Type: EXPERIMENTAL; Interventions: Drug: Pembrolizumab - 4 cycle | Arm Label: Talazoparib plus Irinotecan; Type: EXPERIMENTAL; Interventions: Drug: Talazoparib plus Irinotecan | Arm Label: Patritumab with or without Trastuzumab; Type: EXPERIMENTAL; Interventions: Drug: Patritumab and Trastuzumab | Arm Label: Pembrolizumab 8 cycle; Type: EXPERIMENTAL; Interventions: Drug: Pembrolizumab - 8 cycle | Arm Label: SGN-LIV1A; Type: EXPERIMENTAL; Interventions: Drug: SGN-LIV1A | Arm Label: Durvalumab plus Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Durvalumab plus Olaparib | Arm Label: SD-101 + Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: SD-101 + Pembrolizumab | Arm Label: Tucatinib; Type: EXPERIMENTAL; Interventions: Drug: Tucatinib plus trastuzumab and pertuzumab | Arm Label: Cemiplimab; Type: EXPERIMENTAL; Interventions: Drug: Cemiplimab | Arm Label: Cemiplimab plus REGN3767; Type: EXPERIMENTAL; Interventions: Drug: Cemiplimab plus REGN3767 | Arm Label: Trilaciclib with or without trastuzumab + pertuzumab; Type: EXPERIMENTAL; Interventions: Drug: Trilaciclib with or without trastuzumab + pertuzumab | Arm Label: SYD985 ([vic-]trastuzumab duocarmazine); Type: EXPERIMENTAL; Interventions: Drug: SYD985 ([vic-]trastuzumab duocarmazine) | Arm Label: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab; Type: EXPERIMENTAL; Interventions: Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab | Arm Label: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab; Type: EXPERIMENTAL; Interventions: Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab | Arm Label: Endocrine Optimization Pilot: Amcenestrant Monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Amcenestrant | Arm Label: Endocrine Optimization Pilot: Amcenestrant + Abemaciclib; Type: EXPERIMENTAL; Interventions: Drug: Amcenestrant + Abemaciclib | Arm Label: Endocrine Optimization Pilot: Amcenestrant + Letrozole; Type: EXPERIMENTAL; Interventions: Drug: Amcenestrant + Letrozole | Arm Label: ARX788 in Block A and followed by SOC in Block B; Type: EXPERIMENTAL; Interventions: Drug: ARX788 | Arm Label: ARX788 + Cemiplimab in Block A and followed by SOC in Block B; Type: EXPERIMENTAL; Interventions: Drug: ARX788 + Cemiplimab | Arm Label: VSV-IFNβ-NIS (VOYAGER V1™; VV1) + Cemiplimab in Block A and followed by SOC in block B; Type: EXPERIMENTAL; Interventions: Drug: VV1 + Cemiplimab | Arm Label: Datopotamab Deruxtecan in Block A and followed by SOC in block B; Type: EXPERIMENTAL; Interventions: Drug: Datopotamab deruxtecan | Arm Label: Datopotamab Deruxtecan + Durvalumab in Block A and followed by SOC in block B; Type: EXPERIMENTAL; Interventions: Drug: Datopotamab deruxtecan + Durvalumab | Arm Label: Zanidatamab in Block A and followed by SOC in block B; Type: EXPERIMENTAL; Interventions: Drug: Zanidatamab | Arm Label: Endocrine Optimization Pilot: Lasofoxifene; Type: EXPERIMENTAL; Interventions: Drug: Lasofoxifene | Arm Label: Endocrine Optimization Pilot: (Z)-Endoxifen; Type: EXPERIMENTAL; Interventions: Drug: Z-endoxifen | Arm Label: Endocrine Optimization Pilot: ARV-471; Type: EXPERIMENTAL; Interventions: Drug: ARV-471 | Arm Label: Endocrine Optimization Pilot: ARV-471 + Letrozole; Type: EXPERIMENTAL; Interventions: Drug: ARV-471 + Letrozole | Arm Label: Endocrine Optimization Pilot: ARV-471 + Abemaciclib; Type: EXPERIMENTAL; Interventions: Drug: ARV-471 + Abemaciclib | Arm Label: Endocrine Optimization Pilot: (Z)-Endoxifen + Abemaciclib; Type: EXPERIMENTAL; Interventions: Drug: Endoxifen + Abemaciclib | Arm Label: Rilvegostomig + TDXd in Block A and followed by SOC in Block B; Type: EXPERIMENTAL; Interventions: Drug: Rilvegostomig + TDXd | Arm Label: DAN222 + Niraparib in Block A and followed by SOC in Block B; Type: EXPERIMENTAL; Interventions: Drug: Dan222 + Niraparib | Arm Label: Sarilumab + Cemiplimab + Paclitaxel in Block B followed by SOC Block C; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab + Cemiplimab + Paclitaxel | Intervention Type: DRUG; Name: Standard Therapy; Assigned to Arm(s): Standard Therapy | Intervention Type: DRUG; Name: AMG 386 with or without Trastuzumab; Assigned to Arm(s): AMG 386 with or without Trastuzumab | Intervention Type: DRUG; Name: AMG 479 (Ganitumab) plus Metformin; Assigned to Arm(s): AMG 479 plus Metformin | Intervention Type: DRUG; Name: MK-2206 with or without Trastuzumab; Assigned to Arm(s): MK-2206 with or without Trastuzumab | Intervention Type: DRUG; Name: AMG 386 and Trastuzumab; Assigned to Arm(s): AMG 386 with or without Trastuzumab | Intervention Type: DRUG; Name: T-DM1 and Pertuzumab; Assigned to Arm(s): T-DM1 and Pertuzumab | Intervention Type: DRUG; Name: Pertuzumab and Trastuzumab; Assigned to Arm(s): Pertuzumab and Trastuzumab | Intervention Type: DRUG; Name: Ganetespib; Assigned to Arm(s): Ganetespib | Intervention Type: DRUG; Name: ABT-888; Assigned to Arm(s): ABT-888 | Intervention Type: DRUG; Name: Neratinib; Assigned to Arm(s): Neratinib | Intervention Type: DRUG; Name: PLX3397; Assigned to Arm(s): PLX3397 | Intervention Type: DRUG; Name: Pembrolizumab - 4 cycle; Assigned to Arm(s): Pembrolizumab 4 cycle | Intervention Type: DRUG; Name: Talazoparib plus Irinotecan; Assigned to Arm(s): Talazoparib plus Irinotecan | Intervention Type: DRUG; Name: Patritumab and Trastuzumab; Assigned to Arm(s): Patritumab with or without Trastuzumab | Intervention Type: DRUG; Name: Pembrolizumab - 8 cycle; Assigned to Arm(s): Pembrolizumab 8 cycle | Intervention Type: DRUG; Name: SGN-LIV1A; Assigned to Arm(s): SGN-LIV1A | Intervention Type: DRUG; Name: Durvalumab plus Olaparib; Assigned to Arm(s): Durvalumab plus Olaparib | Intervention Type: DRUG; Name: SD-101 + Pembrolizumab; Assigned to Arm(s): SD-101 + Pembrolizumab | Intervention Type: DRUG; Name: Tucatinib plus trastuzumab and pertuzumab; Assigned to Arm(s): Tucatinib | Intervention Type: DRUG; Name: Cemiplimab; Assigned to Arm(s): Cemiplimab | Intervention Type: DRUG; Name: Cemiplimab plus REGN3767; Assigned to Arm(s): Cemiplimab plus REGN3767 | Intervention Type: DRUG; Name: Trilaciclib with or without trastuzumab + pertuzumab; Assigned to Arm(s): Trilaciclib with or without trastuzumab + pertuzumab | Intervention Type: DRUG; Name: SYD985 ([vic-]trastuzumab duocarmazine); Assigned to Arm(s): SYD985 ([vic-]trastuzumab duocarmazine) | Intervention Type: DRUG; Name: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab; Assigned to Arm(s): Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab | Intervention Type: DRUG; Name: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab; Assigned to Arm(s): Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab | Intervention Type: DRUG; Name: Amcenestrant; Assigned to Arm(s): Endocrine Optimization Pilot: Amcenestrant Monotherapy | Intervention Type: DRUG; Name: Amcenestrant + Abemaciclib; Assigned to Arm(s): Endocrine Optimization Pilot: Amcenestrant + Abemaciclib | Intervention Type: DRUG; Name: Amcenestrant + Letrozole; Assigned to Arm(s): Endocrine Optimization Pilot: Amcenestrant + Letrozole | Intervention Type: DRUG; Name: ARX788; Assigned to Arm(s): ARX788 in Block A and followed by SOC in Block B | Intervention Type: DRUG; Name: ARX788 + Cemiplimab; Assigned to Arm(s): ARX788 + Cemiplimab in Block A and followed by SOC in Block B | Intervention Type: DRUG; Name: VV1 + Cemiplimab; Assigned to Arm(s): VSV-IFNβ-NIS (VOYAGER V1™; VV1) + Cemiplimab in Block A and followed by SOC in block B | Intervention Type: DRUG; Name: Datopotamab deruxtecan; Assigned to Arm(s): Datopotamab Deruxtecan in Block A and followed by SOC in block B | Intervention Type: DRUG; Name: Datopotamab deruxtecan + Durvalumab; Assigned to Arm(s): Datopotamab Deruxtecan + Durvalumab in Block A and followed by SOC in block B | Intervention Type: DRUG; Name: Zanidatamab; Assigned to Arm(s): Zanidatamab in Block A and followed by SOC in block B | Intervention Type: DRUG; Name: Lasofoxifene; Assigned to Arm(s): Endocrine Optimization Pilot: Lasofoxifene | Intervention Type: DRUG; Name: Z-endoxifen; Assigned to Arm(s): Endocrine Optimization Pilot: (Z)-Endoxifen | Intervention Type: DRUG; Name: ARV-471; Assigned to Arm(s): Endocrine Optimization Pilot: ARV-471 | Intervention Type: DRUG; Name: ARV-471 + Letrozole; Assigned to Arm(s): Endocrine Optimization Pilot: ARV-471 + Letrozole | Intervention Type: DRUG; Name: ARV-471 + Abemaciclib; Assigned to Arm(s): Endocrine Optimization Pilot: ARV-471 + Abemaciclib | Intervention Type: DRUG; Name: Endoxifen + Abemaciclib; Assigned to Arm(s): Endocrine Optimization Pilot: (Z)-Endoxifen + Abemaciclib | Intervention Type: DRUG; Name: Rilvegostomig + TDXd; Assigned to Arm(s): Rilvegostomig + TDXd in Block A and followed by SOC in Block B | Intervention Type: DRUG; Name: Dan222 + Niraparib; Assigned to Arm(s): DAN222 + Niraparib in Block A and followed by SOC in Block B | Intervention Type: DRUG; Name: Sarilumab + Cemiplimab + Paclitaxel; Assigned to Arm(s): Sarilumab + Cemiplimab + Paclitaxel in Block B followed by SOC Block C
C: Arm Label: Pembrolizumab + Chemotherapy; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Carboplatin, Drug: Paclitaxel, Drug: Doxorubicin, Drug: Epirubicin, Drug: Cyclophosphamide, Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim | Arm Label: Placebo + Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Doxorubicin, Drug: Epirubicin, Drug: Cyclophosphamide, Drug: Placebo, Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab + Chemotherapy | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Pembrolizumab + Chemotherapy, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Pembrolizumab + Chemotherapy, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Pembrolizumab + Chemotherapy, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): Pembrolizumab + Chemotherapy, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Pembrolizumab + Chemotherapy, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Chemotherapy | Intervention Type: BIOLOGICAL; Name: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim; Assigned to Arm(s): Pembrolizumab + Chemotherapy, Placebo + Chemotherapy
D: Arm Label: PM(Cb); Type: EXPERIMENTAL; Interventions: Drug: non-pegylated liposomal doxorubicin, Drug: Carboplatin, Drug: Paclitaxel, Drug: Pertuzumab, Drug: Trastuzumab, Drug: Ferric carboxymaltose | Arm Label: ETC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Epirubicin, Drug: Cyclophosphamide, Drug: Pertuzumab, Drug: Trastuzumab, Drug: Ferric carboxymaltose | Intervention Type: DRUG; Name: non-pegylated liposomal doxorubicin; Assigned to Arm(s): PM(Cb) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): PM(Cb) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): ETC, PM(Cb) | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): ETC | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): ETC | Intervention Type: DRUG; Name: Pertuzumab; Assigned to Arm(s): ETC, PM(Cb) | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): ETC, PM(Cb) | Intervention Type: DRUG; Name: Ferric carboxymaltose; Assigned to Arm(s): ETC, PM(Cb)

Answer: A